| abstract |
Provided is a novel pharmaceutical composition that is effective for treating a disease, which is based on overexpression of monocyte chemotactic protein-1 (MCP-1) or is simultaneously affected by overexpression of MCP-1. An antihypertensive drug selected from 1-benzyl-3-hydroxymethylindazole derivatives, ACE inhibitors such as captolyl, ARBs such as candesartan, and CCBs such as amlodipine, and / or a statin derivative such as lovastatin Or a pharmaceutical composition comprising at least one cholesterol-lowering drug selected from pharmaceutically acceptable salts and esters thereof and at least one pharmaceutically acceptable excipient. [Effects] The combination exhibits additional and synergistic activity to lower MCP-1 levels, thus greatly improving the suppression of inflammatory response and consequently reducing complications arising in patients suffering from inflammatory diseases Let [Selection] Figure 1 |